Study details
Enrolling now
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT IDNCT05985161ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
45
Study length
about 6 years
Ages
1+
Locations
15 sites in CA, DC, GA +6
About this study
Researchers are testing whether selinexor, a medication, can be an effective treatment for people with relapsed or refractory Wilms tumors, rhabdoid tumors, MPNSTs, or other solid tumors that make too much XPO1. The trial will last approximately 2 years and aims to enroll about 45 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Selinexor
PhasePhase 2
DrugSelinexor
Routeoral
Primary goalOverall Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
selinexor
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Overall Response Rate
Body systems
Oncology